Results 121 to 130 of about 1,655 (156)

Psychedelic therapy and postpartum depression: priorities and prospects. [PDF]

Ther Adv Psychopharmacol
Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, Harkin A, Kelly JR.   +7 more
europepmc   +1 more source

Potential molecular pathways and therapeutic implications of rapid-acting antidepressants on myelin biology: a scoping review. [PDF]

Front Neurosci
Inserra A, Murray CJ, Campanale A, VanderZwaag J, Tremblay MÈ.   +4 more
europepmc   +1 more source

Motor fatigue and fatigability in early multiple sclerosis patients: an analysis of clinical, radiological and psychological underpinnings. [PDF]

Neurol Sci
Betti M, Masciulli C, Addazio I, Ballerini C, Bonacchi R, Caporali A, Chiappetta F, De Meo E, Fabbiani C, Gerli F, Kihlbom U, Niccolai C, Pasquini G, Pastò L, Penati V, Bywall KS, Johansson JV, Fainardi E, Martin S, Portaccio E, Amato MP.   +20 more
europepmc   +1 more source

Fatalities following DMT use: two case reports and a review of the literature. [PDF]

J Anal Toxicol
Pullen J, Moore R, Wood R, Rab E, Couchman L, Copeland CS.   +5 more
europepmc   +1 more source

Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. [PDF]

Transl Psychiatry
Lima da Cruz RV, Costa RBGM, de Queiroz GM, Stojanovic T, Moulin TC, Leão RN.   +5 more
europepmc   +1 more source

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments. [PDF]

Neurology
De Meo E, Addazio I, Portaccio E, Bonacchi R, Betti M, Patti F, Guerrieri S, Foschi M, Ferraro D, Annovazzi P, Brescia Morra V, Tortorella C, Lugaresi A, Camilli F, Pozzilli C, Perini P, Granella F, De Luca G, Torri Clerici VLAM, Vianello M, Romano S, Cocco EE, Lus G, Di Sapio A, Rocca MA, Simone M, Iaffaldano P, Filippi M, Trojano M, Amato MP.   +29 more
europepmc   +1 more source

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential. [PDF]

Mol Psychiatry
Puigseslloses P, Nadal-Gratacós N, Fumàs B, Modenutti CP, Pottie E, Ortigosa JR, Pablo-Quesada A, Riera-Colomer C, Ettcheto M, Berzosa X, Pubill D, Stove C, Escubedo E, López-Arnau R.   +13 more
europepmc   +1 more source

Speech markers of psychedelic-induced psychological change

Kuc J, McAlpine RG, Sellers A, Blackburne G, Lametti DR, Skipper JI.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology, 2023
5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to ...
Robin Carhart-Harris, Otto Simonsson, Haley Dourron   +2 more
exaly   +3 more sources

Defining 5-MeO-DMT in Historical and Cultural Contexts

World Futures
Azul DelGrasso
exaly   +2 more sources